Keros Therapeutics, Inc. (KROS) Financials

KROS Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 287.6 million 25.3 million
March 31, 2026 312.3 million 26.7 million
Dec. 31, 2025 338.0 million 34.9 million
Sept. 30, 2025 742.8 million 39.2 million

KROS Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -20.6 million 5.4 million
March 31, 2026 -3.6 million 6.2 million
Dec. 31, 2025 -27.4 million 7.3 million
Sept. 30, 2025 3.1 million 4.0 million

KROS Net Income

No data available :(

KROS Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 257.6 million 13.1 million 15.7 million
March 31, 2026 281.5 million 13.8 million 2.5 million
Dec. 31, 2025 287.4 million - 16.9 million
Sept. 30, 2025 693.5 million - 17.4 million

KROS Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 19.8 million
March 31, 2026 19.6 million
Dec. 31, 2025 27.2 million
Sept. 30, 2025 40.6 million

KROS Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 155000 22.3 million 8.6 million -
March 31, 2026 73000 16.1 million 10.1 million -
Dec. 31, 2025 134000 17.9 million 11.7 million -
Sept. 30, 2025 132000 19.5 million 10.1 million -

KROS Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 18.2 million -
March 31, 2026 367000 403000
Dec. 31, 2025 385000 400000
Sept. 30, 2025 14.3 million 395000

KROS Revenue by Segment
Graph available only for paid members. Upgrade to see it.

KROS

Price: $10.66

52 week price:
9.69
22.55

Earnings Per Share: -3.22 USD

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 412500

Market Capitalization: 225.2 million

Links: